MONROE / INDEPENDENT RESEARCH CATALOGUENot sure where to begin? Use guided discovery

Currency

Shop 0 Find my pathway

Peptipedia / Research subject

Retatrutide

Publications on retatrutide and its investigational GIP, GLP-1 and glucagon receptor agonism.

Explore the papers.

6 publications

2026 JanDiabetes, obesity & metabolism
Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials.
Giblin K, Kaplan LM, Somers VK et al.
PubMed · PMID 41090431Journal article
2025 AugThe lancet. Diabetes & endocrinology
Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial.
Coskun T, Wu Q, Schloot NC et al.
PubMed · PMID 40609566Randomized Controlled Trial · Clinical Trial, Phase II
2025 May 30Biomolecules
Retatrutide-A Game Changer in Obesity Pharmacotherapy.
Katsi V, Koutsopoulos G, Fragoulis C et al.
PubMed · PMID 40563436Review
2024 Dec 15European journal of pharmacology
The power of three: Retatrutide's role in modern obesity and diabetes therapy.
Abdul-Rahman T, Roy P, Ahmed FK et al.
PubMed · PMID 39515565Review
2024 JulNature medicine
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.
Sanyal AJ, Kaplan LM, Frias JP et al.
PubMed · PMID 38858523Randomized Controlled Trial · Clinical Trial, Phase II
2022 Sep 6Cell metabolism
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept.
Coskun T, Urva S, Roell WC et al.
PubMed · PMID 35985340Journal article